Book Value per Share: Cerevel (CERE)

Cerevel Therapeutics (CERE) - corporate logo

The risks of narrow specialization in schizophrenia and Parkinson's therapies were mitigated by a merger with a major player. The capital per share level visualizes this process, where the 3.12 mark characterizes this parameter. Asset growth is driven by the potential of emraclidine and the AbbVie acquisition, while high profitability from mass drug production offsets the costs of neurobiological research for Cerevel Therapeutics (CERE).

Cerevel Therapeutics Inc (CERE) Equity per Share: for the period 07/04/2022 - 08/10/2024

cerevel.com - analytical breakdowns and key metrics (CERE)

- price and consensus price forecast:
Price Chart Cerevel|CERE - Fair Value Consensus
- market capitalization data:
Market Capitalization Cerevel Therapeutics, Inc.|CERE - Total Enterprise Value
- book capitalization data:
Net Assets per Single Share Cerevel Therapeutics|CERE - Accounting Capitalization|Market Capitalization to Book Value Ratio cerevel.com|CERE - Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Cerevel Therapeutics|CERE - Long-Term Debt to Capital|Short-Term Debt to Equity Cerevel Therapeutics, Inc.|CERE - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Cerevel Therapeutics, Inc.|CERE - Long-Term Debt|Company Short-Term Debts Cerevel Therapeutics
Fundamental company valuation:Cerevel, CERE
Manufactured products of Cerevel Therapeutics, Inc.

The metric is calculated as the ratio of equity minus intangible assets to the number of shares, reflecting the actual net asset value per share. The trend in book value per share at Cerevel Therapeutics (CERE) confirms the capitalization of resources into the modernization of clean rooms and CNS laboratories, transforming financial reserves into production capacity for clinical batch manufacturing.

Competitors of Cerevel Therapeutics (CERE)

Net Assets per Single Share Biogen Corp (BIIB)|NBIX - Accounting Value of a Share|Book Value per Share RGC|AXSM (axsome.com) - Net Asset Value per Share|Net Assets per Single Share ACADIA Pharmaceuticals Inc. (ACAD)|Equity per Share Xenon Pharmaceuticals Inc.|Viking Pharma - Book Value per Share|Net Asset Value per Share Supernus Corp SUPN|Accounting Value per Share CPRX (Catalyst Pharmaceuticals)|denalitherapeutics.com - Book Value per Share|Net Assets per Single Share Harmony Biosciences Holdings, Inc. (HRMY)|BHVN: Accounting Value of a Share|Net Assets per Single Share AMLX|Trevi Corp (TRVI) - Net Asset Value per Share|Book Value per Share PRAX|Accounting Value per Share anavex.com|CeriBell - Book Value per Share|Net Asset Value per Share PRTA (Prothena Corporation)|Net Assets per Single Share Alector|Accounting Value of a Share Annexon Biosciences Inc. ANNX|OMER (Omeros Corp.) - Book Value per Share|neurogene.com (NGNE) - Net Asset Value per Share|AC Immune SA (ACIU) - Accounting Value per Share|Voyager Therapeutics Inc (VYGR) - Net Assets per Single Share|Book Value per Share NMRA (Neumora Therapeutics Inc)|Net Asset Value per Share SCLX|Net Assets per Single Share Tevogen Bio Holdings (TVGN)|Net Assets per Single Share alphacognition.com ACOG|Accounting Value per Share Cognition Therapeutics|IKT - Accounting Value of a Share|Accounting Value per Share Cassava SAVA|ASRT - Book Price of a Share|Book Value per Share coyatherapeutics.com COYA|Vistagen (VTGN) - Accounting Value of a Share|Book Value per Share OVID (Ovid Therapeutics Inc)|Net Asset Value per Share ABOS|CervoMed Inc (CRVO) - Net Assets per Single Share|Accounting Value of a Share alteritytherapeutics.com (ATHE)|Book Value per Share CLNN (Clene)|PepGen Inc - Book Value per Share|Net Assets per Single Share Jupiter Neurosciences Inc|RLMD - Share Book Value|Book Value per Share ANVS|Net Asset Value per Share Grace Therapeutics|AIFF (Firefly Neuroscience, Inc) - Accounting Value per Share|Book Value per Share ANEW Medical, Inc. (KLTO)|Accounting Value per Share NeuroSense Therapeutics|Book Price of a Share Reviva Pharmaceuticals Holdings Inc. (RVPH)|Book Value per Share MTVA|Net Assets per Share NeurAxis Inc NRXS|HSDT: Book Value per Share|PASG: Accounting Value per Share|bionomics.com.au - Net Assets per Single Share|Minerva Neurosciences Inc (NERV) - Net Assets per Share|Book Value per Share ATHA|Accounting Value per Share Addex|Alzamend Neuro, Inc. - Book Value per Share|Net Asset Value per Share CYCN (cyclerion.com)|Net Assets per Single Share Protagenic Therapeutics, Inc.|Accounting Value of a Share Pasithea Therapeutics Corp KTTA|CRGT (Cortigent Medical) - Book Value per Share|ATXI: Net Asset Value per Share|Net Assets per Single Share Brainstorm Cell|caratherapeutics.com (CARA) - Equity per Share|Book Value per Share CHRO (Chromocell Therapeutics Corp.)|Net Asset Value per Share Eliem (ELYM)|Accounting Value per Share ITCI|Book Value per Share LBPH (Longboard)|Net Assets per Single Share Marinus Pharmaceuticals|nkgenbiotech.com - Accounting Value of a Share|NRBO (NeuroBo Pharmaceuticals, Inc.) - Net Assets per Single Share|SAGE - Net Asset Value per Share|SNPX (Neurotrope) - Book Value per Share|Trevena Inc (TRVN) - Accounting Value per Share|Book Value per Share VIGL (Vigil Neuroscience Inc.)|Net Asset Value per Share WENA